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Background: C-reactive protein level (CRP) and white blood cell count (WBC) have
been variably used in clinical trials on acute pancreatitis (AP). We assessed their
potential role.
Methods: First, we investigated studies which have used CRP or WBC, to describe
their current role in trials on AP. Second, we extracted the data of 1435 episodes of AP
from our registry. CRP and WBC on admission, within 24 h from the onset of pain and
their highest values were analyzed. Descriptive statistical tools as Kruskal–Wallis, Mann–
Whitney U, Levene’s F tests, Receiver Operating Characteristic (ROC) curve analysis and
AUC (Area Under the Curve) with 95% confidence interval (CI) were performed.
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Results: Our literature review showed extreme variability of CRP used as an inclusion
criterion or as a primary outcome or both in past and current trials on AP. In our
cohort, CRP levels on admission poorly predicted mortality and severe cases of AP;
AUC: 0.669 (CI:0.569–0.770); AUC:0.681 (CI: 0.601–0.761), respectively. CRP levels
measured within 24 h from the onset of pain failed to predict mortality or severity;
AUC: 0.741 (CI:0.627–0.854); AUC:0.690 (CI:0.586–0.793), respectively. The highest
CRP during hospitalization had equally poor predictive accuracy for mortality and
severity AUC:0.656 (CI:0.544–0.768); AUC:0.705 (CI:0.640–0.769) respectively. CRP
within 24 h from the onset of pain used as an inclusion criterion markedly increased the
combined event rate of mortality and severe AP (13% for CRP > 25 mg/l and 28% for
CRP > 200 mg/l).
Conclusion: CRP within 24 h from the onset of pain as an inclusion criterion elevates
event rates and reduces the number of patients required in trials on AP.
Keywords: acute pancreatitis, C-reactive protein, white blood cell, trial design, sample size calculation
INTRODUCTION
Acute pancreatitis (AP) is one of the most common acute
gastrointestinal pathology needing hospitalization in the
United States (Peery et al., 2012). It is often mild, but in
moderate and severe cases it can have a mortality of around
30% despite current treatment options (Gompertz et al., 2013;
Parniczky et al., 2016). In our previous cohort analysis on the
first 600 subjects recorded in our multicentric, and multinational
AP database severe disease developed in 8.8% of all cases
(Parniczky et al., 2016).
There are few clinical trials on AP despite its burden (Szentesi
et al., 2016). There were 183 registered clinical studies on
ClinicalTrials.gov in November 2018. This is in the context of
1914 studies on IBD, 395 on Helicobacter pylori and 235 on
colonic polyps registered at the same time.
High-quality clinical trials on AP are difficult to conduct
as the most important clinical outcomes, such as severe acute
pancreatitis (SAP) and death, have low event rates (Gompertz
et al., 2013; Parniczky et al., 2016). Furthermore, at the time of
the diagnosis of AP, the disease course and outcome are difficult
to predict (Cho et al., 2015). As a result, there are many trials on
AP that have been designed with primary outcomes other than
mortality and SAP.
The most obvious and simplest markers of inflammation are
C-reactive protein level (CRP) and white blood cell count
(WBC). They are widely available and readily reported
in nearly any healthcare settings. Therefore, trials on
AP have been using inflammatory markers as inclusion
criteria and as primary outcomes too. However, there is no
currently available evidence-based information and practical
guideline on their use.
Our aim was to assess the past and current role of CRP and
WBC in clinical trials on AP and to provide evidence from a
high-quality large multinational cohort analysis to guide clinical
researchers on the most appropriate role of CRP and WBC in
future clinical trials.
MATERIALS AND METHODS
The Two Main Domains
First, we reviewed the studies on AP that have used CRP or WBC
as inclusion criterion or as an outcome to understand their past
and current role.
Second, we analyzed data from a large prospectively collected
cohort of AP patients to assess the potential future role of CRP
and WBC in the design of trials.
Literature Review
We searched PubMed on January 9, 2019 for the query:
random∗ AND “acute pancreatitis.” The records were managed
by EndNote X7.4, software (Clarivate Analytics, Philadelphia,
PA, United States). Studies published before January 1, 2000
were excluded. The records were screened by title, by abstract
and by full text.
In addition, we searched the study registries ClinicalTrials.gov
and International Standard Randomised Controlled Trial
Number (ISRCTN) by using the query “acute pancreatitis” on
15/01/2019 for ongoing studies on AP.
Studies from both searches were selected that used CRP
or WBC as an inclusion criterion or primary outcome
in trials on AP.
The aggregated yield of both search strategies was
screened and data were extracted on the role, timing, and
thresholds of CRP and WBC.
Cohort Analysis
The Setting of the Study and the Database
Subjects with AP were enrolled in our large multicentric and
multinational registry on AP hospitalization from 13 countries
and 29 centers (Supplementary Figure 1). Their detailed data
were uploaded to the database for the hospitalization of AP.
The project was approved by the Scientific and Research Ethics
Committee of the Medical Research Council on August 15,
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2012 (22254-1/2012/EKU), also by the participating centers’
ethical boards and subjects in the study provided informed
and written consent. The study protocol conforms to the
ethical guidelines of the 1975 Declaration of Helsinki as
reflected in a priori approval by the institution’s human research
committee. Information on the quality of data is provided in the
Supplementary Table 1.
Definition of Acute Pancreatitis
Acute pancreatitis was defined as the presence of at least two of
the following criteria: abdominal pain, at least threefold rise in
the pancreatic enzymes and evidence of pancreatitis on imaging
(Banks et al., 2013). Severity grades were defined by the modified
Atlanta criteria (Banks et al., 2013).
Measurement of CRP and WBC
This database includes data from multiple centers and all
contributing centers complied with all the necessary laboratory
requirements and guidelines. CRP and WBC were uploaded onto
the prospective database in units of mg/l and G/l, respectively.
If local measurements used different units then the results were
calculated and recorded in the above units.
Data Extraction
We extracted data on the onset of pain, CRP, WBC, demographics
(age and gender) and etiology, severity, and mortality of AP.
Data extraction included patients enrolled between August 2012
and September 2017.
Statistical Analysis
Prior to the analysis of the dataset, descriptive statistical tools
were used to describe the basic characteristics. To observe
differences between the severity groups, we applied Kruskal–
Wallis test with Mann–Whitney U-test as post hoc, because of
the non-parametric behavior of the variables. The beginning of
pain before admission influences the levels of the inflammatory
parameters, therefor the CRP and WBC levels on admission
were adjusted for the duration of pain. For verification of this
statement, the homoscedasticity of the original and corrected
on admission CRP and WBC were examined with Levene’s F
test. Receiver Operating Characteristic (ROC) curve analysis and
AUC (Area Under the Curve) with 95% confidence interval
(CI) determination were used to check the ability of CRP and
WBC for classification of severity and mortality. According to
the value of AUC, the accuracy of the test can be classified as
followed: 0.5–0.6 fail, 0.6–0.7 poor, 0.7–0.8 fair, 0.8–0.9 good
and above 0.9 excellent. All analyses were conducted using IBM-
SPSS Statistical Software version 25 (IBM Corporation, Armonk,
NY, United States).
RESULTS
Role of CRP and WBC in Past and
Ongoing Clinical Studies
Our search criteria yielded a total of 2021 records. After the
exclusion of studies from before 2000, there were 1664 left. After
screening by title 136 eligible abstracts remained and 107 full-text
articles were reviewed. This strategy identified 17 studies where
CRP was an inclusion criterion, 10 studies where CRP was a
primary outcome (Powell et al., 2000; Louie et al., 2004; Pearce
et al., 2006; Guo et al., 2013; Sun et al., 2013; Cui et al., 2014; Vege
et al., 2015; Choosakul et al., 2018; de-Madaria et al., 2018; Jin
et al., 2018) and two studies where CRP was both an inclusion
criterion and primary outcome.
We found three studies on ClinicalTrials.gov where
CRP is a primary outcome (NCT03686618, NCT02692391,
NCT02885441) and two studies where CRP is an inclusion
criterion (NCT00894907, NCT03082469). A further study was
registered both on ClinicalTrials.gov and ISRCTN which uses
CRP as a primary outcome (NCT03684278, ISRCTN16935761).
Furthermore, CRP was used as a variable inclusion criterion.
Twelve studies used a cut off level of 150 mg/l, four
studies 120 mg/l, and three studies 100 mg/l (NCT00894907,
NCT03082469). One study specified a cut off level at 120 mg/l
within 24 h from admission and 200 mg/l within 48 h from
admission and another study just mentions elevated CRP. One
study required high CRP on admission, two studies within 24,
and one study within 48 h from admission. From the onset of
symptoms six studies required CRP within 48 (NCT00894907,
NCT03082469), four studies within 72, one study within 120 h
and six studies did not specify the timeframe. The details and
the references are shown in the Supplementary Table 2 and
Supplementary References.
White blood cell count is used as an optional inclusion
criterion only in two studies with a cut off level of > 16G/l.
Data Quality, Demographics, and Basic
Characteristics of the Cohort
Our analysis included data of 1435 episodes of AP. We had
100% data on age, gender, severity, mortality, and length of
hospitalization. WBC and CRP on admission were available in
1288 (89.9%) and 1177 cases (82.0%), respectively. WBC and
CRP, within 24 h from the onset of pain, were available in
691 (48.2%) and in 627 patients (43.7%) respectively. There
were 79 (5.51%) severe, 371 (25.85%) moderately severe, 985
(68.64%) mild AP, and altogether 34 patients died (2.37%). The
details of the descriptive statistics (demographics, etiology) of
the cohort are shown in the Supplementary Figure 2. Further
details of the data on CRP level and WBC count are shown
in Supplementary Figures 4–6.
On Admission CRP Cannot Predict the
Mortality or Severity
On admission median CRPs were directly associated with the
severity of AP, 14.90 (IQR: 5.00–54.60) mg/l in mild, 26.90 (IQR:
6.93–105.95) mg/l in moderately severe, and 83.30 (IQR: 13.50–
222.70) mg/l in severe (mild vs. moderately severe, p < 0.001;
mild vs. severe, p < 0.001; moderately severe vs. severe AP,
p = 0.01) (Figure 1A).
Receiver Operating Characteristic analyses showed poor
predictive accuracy of CRP on admission for mortality and severe
AP, AUC: 0.669 (CI: 0.569–0.770) (Figure 1B) and AUC: 0.681
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FIGURE 1 | On admission CRP; (A) median CRP for severity grades of acute pancreatitis (AP), (B) predictive accuracy for mortality of AP, (C) predictive accuracy for
severe AP, (D) predictive accuracy for mild AP. On admission WBC; (E) median WBC for severity grades of AP, (F) predictive accuracy for mortality of AP (G)
predictive accuracy for severe AP, and (H) predictive accuracy for mild AP.
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FIGURE 2 | C-reactive protein level within 24 h from the onset of pain; (A) median CRP for severity grades of acute pancreatitis (AP), (B) predictive accuracy for
mortality of AP, (C) predictive accuracy for severe AP, (D) predictive accuracy for mild AP. WBC within 24 h from the onset of pain; (E) median WBC for severity
grades of AP, (F) predictive accuracy for mortality of AP, (G) predictive accuracy for severe AP, and (H) predictive accuracy for mild AP.
Frontiers in Physiology | www.frontiersin.org 5 September 2019 | Volume 10 | Article 1092
fphys-10-01092 September 4, 2019 Time: 13:18 # 6
Farkas et al. Information for Trial Design in Acute Pancreatitis
(CI: 0.601–0.761) (Figure 1C) respectively, and it failed to predict
mild AP, AUC: 0.596 (CI: 0.559–0.663) (Figure 1D).
On Admission, WBC Cannot Predict the
Mortality or Severity
On admission median WBC counts were significantly lower
in mild AP 11.70 (IQR: 9.16–14.80) G/l, than in moderately
severe 14.00 (IQR: 10.50–17.54) G/l and 15.24 (IQR: 11.30–17.95)
G/l in severe AP (mild vs. moderately severe AP, p < 0.001;
mild vs. severe AP, P < 0.001; moderately severe vs. severe AP,
P = 0.987) (Figure 1E).
ROC analyses showed poor predictive accuracy of WBC
on admission for mortality, severe and mild AP, AUC:
0.648 (CI: 0.546–0750) (Figure 1F) and AUC: 0.630 (CI:
0.563–0.696) (Figure 1G) and AUC: 0.631 (CI: 0.598–0.664)
(Figure 1H), respectively.
The CRP Within 24 h From the Onset of
Pain Cannot Predict the Mortality or
Severity
Median CRP within 24 h from the onset of pain were significantly
lower in mild 8.90 (IQR: 3.60–25.10) mg/l and moderately severe
14.60 (IQR: 4.15–60.46) mg/l, than in severe AP 51.45 (IQR:
7.85–175.53) mg/l (mild vs. moderately severe AP: P = 0.006;
mild vs. severe AP: P < 0.001; moderately severe vs. severe AP:
P = 0.059) (Figure 2A).
Receiver Operating Characteristic analyses showed a fair
predictive accuracy of CRP within 24 h for mortality AUC:
0.741 (CI: 0.627–0.854) (Figure 2B) and poor predictive
accuracy for both severe and mild AP, AUC: 0.690 (CI:
0.586-0.793) (Figure 2C) and AUC: 0.604 (CI: 0.554-0.653),
respectively (Figure 2D).
WBC Within 24 h From the Onset of Pain
Cannot Predict the Mortality or Severity
Median of the WBC within 24 h from the onset of pain was
significantly lower in mild 11.70 (IQR: 9.24–14.32) G/l, than in
moderately severe 14.55 (IQR: 10.80–17.51) G/l and in severe
AP 14.60 (IQR: 11.45–18.07) G/l (mild vs. moderately severe AP,
p < 0.001; mild vs. severe AP, P < 0.001; moderately severe vs.
severe AP, P = 1.000) (Figure 2E).
ROC analyses showed poor predictive accuracy of WBC
within 24 h for mortality, severe and mild AP, AUC: 0.616
(CI: 0.490–0.742) (Figure 2F), AUC: 0.631 (CI: 0.547–
0.715) (Figure 2G) and AUC: 0.654 (CI: 0.610–0.698)
(Figure 2H), respectively.
TABLE 1 | The association between on admission C-reactive protein levels (CRP) and white blood cell count (WBC) and the severity and mortality of acute pancreatitis.
CRP
CRP (mg/l) Number of Mild Moderate Severe Mortality Severe or
subjects (n) mortality
n % n % n % n % n %
Total 1177 839 71 283 24 55 5 27 2 65 6
25< 509 329 65 144 28 36 7 18 4 43 8
50< 373 227 61 116 31 30 8 13 3 33 9
75< 280 166 59 86 31 28 10 12 4 30 11
100< 225 127 56 73 32 25 11 10 4 27 12
125< 180 95 53 61 34 24 13 10 6 26 14
150< 130 66 51 45 35 19 15 10 8 21 16
175< 99 46 46 36 36 17 17 9 9 19 19
200< 73 28 38 30 41 15 21 9 12 17 23
WBC
WBC (G/l) Number of Mild Moderate Severe Mortality Severe or
subjects (n) mortality
n % n % n % n % n %
Total 1288 899 70 323 25 66 5 31 2 76 6
10< 904 596 66 255 28 53 6 27 3 62 7
12< 669 421 63 204 30 44 7 22 3 51 8
14< 464 266 57 161 35 37 8 18 4 44 9
16< 321 168 52 125 39 28 9 16 5 33 10
18< 191 100 52 75 39 16 8 11 6 20 10
20< 116 58 50 49 42 9 8 8 7 13 11
22< 74 38 51 31 42 5 7 4 5 7 9
24< 44 20 45 21 48 3 7 3 7 4 9
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Increasing the CRP Level on Admission
as an Inclusion Criterion Elevates the
Event Rates of Severe AP and Mortality
Although CRP cannot predict the severity or mortality of AP,
higher levels on admission increase the event rate of mortality
and severity and their composite. However, a decreasing
proportion of AP patients have higher levels of CRP and WBC
on admission (Table 1).
Limiting the on admission CRP and WBC to patients who
presented within 24 h from the onset of the pain, the potential
number of subjects dropped, but severity and mortality were
higher compared to all admissions (Table 2).
White blood cell count did not show a clear relationship with
the outcomes of AP regardless of the timing of the measurement
(Tables 1, 2).
Analysis of the homoscedasticity of CRP and WBC for the
duration of pain revealed that there were significant differences
between the homoscedasticity of the CRP on day 1, 2, and 4, the
details are in Supplementary Figure 3. Limiting the admission
CRP to those within 24 h from the onset of pain significantly
increased the homoscedasticity P < 0.001 (Figure 3A). The
same limitation did not lead to any significant change in the
homoscedasticity of the WBC, P = 0.632 (Figure 3B).
The Maximum CRP Cannot Predict the
Mortality or Severity
Median of maximum CRP was significantly lower in mild, 95.18
(IQR: 28.73–175.53) mg/l and in moderately severe 213.20 (IQR:
119.20–292.00) mg/l, than in severe AP 232.90 (IQR: 147.50–
333.95) mg/l (mild vs. moderately severe AP, p < 0.001; mild
vs. severe AP, P < 0.001; moderately severe vs. severe AP,
P = 0.729) (Figure 4A).
Receiver Operating Characteristic analyses showed a poor
predictive accuracy of maximum CRP for mortality AUC:
0.656 (CI: 0.544–0.768) (Figure 4B) and a fair predictive
accuracy for both severe and mild AP, AUC: 0.705 (CI:
0.640–0.769) (Figure 4C) and AUC: 0.730 (CI: 0.701–0.760),
respectively (Figure 4D).
The Maximum WBC Cannot Predict the
Mortality or Severity
Median of maximum WBC was directly associated with the
severity of AP, 12.49 (IQR: 9.55–15.68) G/l in mild, 16.16 (IQR:
12.00–20.59) G/l in moderately severe, and 18.63 (IQR: 13.12–
24.30) G/l in severe (mild vs. moderately severe AP, p < 0.001;
mild vs. severe AP, P < 0.001; moderately severe vs. severe AP,
P = 0.016) (Figure 4E).
TABLE 2 | The association between C-reactive protein levels (CRP) and white blood cell count (WBC) within 24 h from the onset of pain and the severity and mortality of
acute pancreatitis.
CRP
CRP (mg/l) Number of Mild Moderate Severe Mortality Severe or
subjects (n) mortality
n % n % n % n % n %
Total 627 430 69 165 26 32 5 18 3 39 6
25< 194 108 56 67 35 19 10 14 7 25 13
50< 131 66 50 49 37 16 12 8 6 17 13
75< 97 50 52 33 34 14 14 7 7 14 14
100< 72 34 47 27 38 11 15 5 7 11 15
125< 59 26 44 22 37 11 19 5 8 11 19
150< 41 17 41 15 37 9 22 5 12 9 22
175< 31 10 32 13 42 8 26 5 16 8 26
200< 25 5 20 13 52 7 28 5 20 7 28
WBC
WBC (G/l) Number of Mild Moderate Severe Mortality Severe or
subjects (n) mortality
n % n % n % n % n %
Total 691 461 67 190 27 40 6 21 3 47 7
10< 494 307 62 154 31 33 7 17 3 38 8
12< 365 213 58 125 34 27 7 14 4 31 8
14< 244 125 51 98 40 21 9 10 4 25 10
16< 171 76 44 79 46 16 9 8 5 18 11
18< 102 47 46 45 44 10 10 7 7 12 12
20< 63 28 44 28 44 7 11 6 10 9 14
22< 38 16 42 19 50 3 8 3 8 4 11
24< 23 9 39 12 52 2 9 2 9 2 9
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FIGURE 3 | (A) Testing of homoscedasticity reveals a significant difference in the dispersion of CRP values limited to the 24 h from the onset of pain, compared to all
on admission CRP values’ dispersions. (B) There is no difference in the dispersion of values of WBC.
Receiver Operating Characteristic analyses for maximum
WBC showed fair predictive accuracy for mortality and
severe AP, AUC: 0.753 (CI: 0.662–0.843) (Figure 4F) and
AUC: 0.724 (CI: 0.667–0.782), respectively (Figure 4G) and
poor predictive accuracy for mild AP 0.689 (CI: 0.659–
0.719) (Figure 4H).
DISCUSSION
Diverse Application of CRP in Past and
Current Clinical Trials on AP Has Been
Lacking High-Quality Evidence
The results of our review proved that CRP is widely used in
studies as an inclusion criterion or primary outcome. CRP is
more commonly used as an inclusion criterion and its use is
highly variable in terms of threshold and timing.
The first study on the role of CRP in the prediction of
the outcome of AP was published by Mayer et al. (1984)
and concluded that high levels of CRP may predict a severe
disease course. Further two studies from the late 1980s drew
the same conclusions and pointed out that CRP was higher
in AP with severe disease course (Puolakkainen et al., 1987;
Wilson et al., 1989).
In most studies where CRP is an inclusion criterion the
authors argue that CRP is a predictor of severe disease based on
past evidence and cite a consensus article from 1999 by Dervenis
et al. (1999), which stated that CRP becomes a good indicator
after 48 h. The authors recommended that CRP > 150 mg/l is
a marker of severity (Dervenis et al., 1999). The problem with
this recommendation is that this consensus is based on data from
old, small, and incomplete studies (Gross et al., 1990; Leser et al.,
1991; Heath et al., 1993; Pezzilli et al., 1995; de Beaux et al.,
1996). At that time, neither the definition nor the classification
of AP were the same as they are now and the measurment of CRP
was less reliable.
More recently the largest study on the assessment of CRP
in AP included 172 patients (Neoptolemos et al., 2000). Other
studies reported data from smaller cohorts (Pongprasobchai
et al., 2010; Vasudevan et al., 2018).
There is only one study analyzing the role of CRP in AP,
since the introduction of revised Atlanta classification, but this
is from a tertiary referral center, where patients were admitted
within 14 days from the onset of disease and there were only 50
subjects enrolled (Vasudevan et al., 2018). This study calculated
a predictive value of CRP with an AUC of 0.8218 for severe AP.
However, we must note that these patients were all well into their
disease course and we know that CRP peaks after day 3 in AP
(Neoptolemos et al., 2000).
In view of the above arguments and the findings of our
literature search, it is clear that CRP is widely used, but there is
a far too great and unjustified variability of its use both in terms
of threshold and its timing.
Role of CRP in Future Clinical Studies
on AP
Based on the results of our analysis, neither CRP nor WBC can
predict mortality or severe disease on the day of admission, even
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FIGURE 4 | Maximum CRP during hospitalization; (A) median CRP for severity grades of acute pancreatitis (AP), (B) predictive accuracy for mortality of AP, (C)
predictive accuracy for severe AP, (D) predictive accuracy for mild AP. Maximum WBC during hospitalization; (E) median WBC for severity grades of AP, (F)
predictive accuracy for mortality of AP, (G) predictive accuracy for severe AP, and (H) predictive accuracy for mild AP.
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TABLE 3 | Based on the composite endpoints of severe acute pancreatitis (AP) for the CRP levels within 24 h form the onset of pain in our cohort we calculated the
sample size for a hypothetical study on AP, in which we would like to demonstrate a 50% reduction of the composite endpoint with 80% statistical power and a P of 0.05.
CRP (mg/l) Number of subjects Severe disease or Estimated sample size in the
within 24 h from in our cohort mortality in our cohort hypothetical study
the onset of pain (composite endpoint)
n % n % Number of patients to be
included in the study
Number of patients with
AP to be screened
0< 627 100 39 6 – –
25< 194 31 25 13 326 1052
50< 131 21 17 13 326 1552
75< 97 15 14 14 300 2000
100< 72 11 11 15 278 2527
125< 59 9 11 19 212 2356
150< 41 7 9 22 178 2543
175< 31 5 8 26 145 2900
200< 25 4 7 28 132 3300
The table clearly demonstrates that we would be able to reduce the number of participants in the study by increasing the inclusion CRP levels, but we would need to
screen an increasing population to find the eligible subjects.
if they are restricted to patients who present within less than 24 h
from the onset of the pain. The AUC for the predictive value
of CRP and WBC regardless their timing did not exceed 0.8,
therefore a cut-off cannot be determined and they should not be
used to predict severity or mortality.
If we accept that studies should aim to analyze effects of
interventions in the early phase of AP as the disease course may
more likely to be influenced, then we have to assess the potential
role of any inclusion criteria on admission and as soon as possible
from the onset of symptoms.
We have shown that CRP limited within 24 h from the onset
of pain can increase the homoscedasticity (Figure 3). Therefore,
we should adjust this parameter for the onset of pain, that is the
duration of the AP.
In order to have the best evidence in the treatment of AP we
believe that mortality and severe disease should be the endpoints
of high-quality trials.
Feasibilty
Our data clearly demonstrates that we would be able to
reduce the number of participants in the study by increasing
the inclusion CRP levels, but we would need to screen
an increasing population to find the eligible subjects as
less and less subjects would fit the inclusion criterion for
enrollment (Tables 1, 2). However, the elevated event rate
of severe disease and mortality could reduce the sample
size of the study population. In other words, it could
compensate clinical researchers for the loss of eligible subjects for
enrollment by reaching sufficient number of hard endpoints in
smaller sample sizes.
Sample Size Calculation
To demonstrate the clinical relevance and potential use of our
findings, we calculated the sample sizes for a hypothetical study
on AP, in which we would like to demonstrate a 50% reduction
of the composite endpoint with 80% statistical power and a P of
0.05 (Table 3).
We would recommend that clinical researchers use CRP
within 24 h from the onset of pain as an inclusion criterion. In
the design process the researchers should set the threshold of
inclusion CRP depending on the practicalities and feasibility of
the planned study.
Inflammatory Markers as Primary
Outcome
Our results demonstrate that the highest detected CRP and WBC
during the course of AP cannot predict the severity or mortality
of the disease (AUC< 0.8) (Figure 4). Therefore, they should not
be used arbitrarily, as primary outcomes in trials on AP.
CONCLUSION
Here we provide high-quality evidence and a method how
to decrease the number of patients required for clinical trials
on AP. We demonstrate that by increasing the CRP levels
measured within 24 h from the onset of abdominal pain
as an inclusion criterion we can elevate the event rates of
mortality, and severity. Investigators can set the inclusion
CRP level tailored for their study purposes and can test
feasibility. Importantly, our data proves that CRP should not
be used as a primary outcome. Finally, WBC should not be
used neither as an inclusion criterion nor as an outcome in
clinical trials on AP.
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